In patients with CKD, decreased antioxidant activity of PON1 predicts an increased risk of adverse cardiovascular events and PON1 concentration has been prospectively associated with cardiovascular mortality and all-cause mortality in patients under renal replacement therapy [158, 178]. The gene discussed is PON1; the disease is chronic kidney disease.